Claritev Corp Dossier - Source-backed chat

Claritev Corp

CTEVNYSE

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)0.87

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $21.31Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $361.2M

Enterprise Value $5B

Shares Outstanding 16.9M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Claritev Corp (formerly MultiPlan Corporation) is executing a strategic turnaround under its 'Vision 2030' plan, driven by digital transformation, AI-enabled operational efficiencies, and expansion into new verticals like government and provider markets. While Q1 2026 results demonstrated solid top-line growth (up 5.8% YoY) and record bookings, the company remains constrained by a highly leveraged balance sheet with over $4.7 billion in debt against a market capitalization of approximately $500 million. Furthermore, escalating legal overhangs—including a price-fixing lawsuit filed by the Arizona Attorney General and ongoing federal multi-district antitrust litigation—pose significant risks to its core out-of-network repricing business model. Consequently, a Hold recommendation is warranted until there is greater clarity on legal resolutions and debt deleveraging.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$37.67

High · most bullish analyst$61.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$22.0020%

Adverse rulings in the Arizona AG price-fixing lawsuit or federal class actions disrupt Claritev's shared-algorithm pricing model, leading to client defections among major insurers (e.g., Aetna, Cigna, UnitedHealth). Debt refinancing becomes difficult or highly dilutive, forcing a restructuring of its $4.7 billion debt load.

Base CaseCentral scenario

$37.6760%

Matches the consensus mean

Claritev achieves its updated FY 2026 revenue guidance of $985 million to $1 billion and Adjusted EBITDA of $605 million to $615 million. Operational efficiencies from AI continue to support a ~60% Adjusted EBITDA margin. However, high interest expenses limit net income, keeping the company in a net loss position, and legal uncertainties continue to cap valuation multiples.

Bull CaseUpside scenario

$61.0020%

Accelerated adoption of AI tools (such as the AI Network Builder and automated coding) drives operating margins higher, while successful expansion into public sector and provider verticals offsets any out-of-network volume declines. Rapid deleveraging occurs as free cash flow turns positive, and major antitrust lawsuits are settled with minimal financial and operational damage.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dominant market position, processing over 80% of out-of-network claims nationwide with a database built on over 45 years of claims repricing experience.
Strong operational cash generation with Adjusted EBITDA margins consistently around 60%.
Successful deployment of AI initiatives, nearly doubling coding capacity without increasing headcount and reducing claim processing times.

Key Investment Risks

Extremely high leverage with over $4.7 billion in total debt, resulting in substantial interest expense and persistent net losses.
Severe legal and regulatory risks from multiple antitrust and price-fixing lawsuits alleging collusion with major health insurers to underpay providers.
Concentration of revenue among a small group of national health insurance payors.

Thesis Invalidation Triggers

Loss of a major health insurer client (e.g., UnitedHealth, Aetna, or Cigna).
A court ruling that outlaws or severely restricts the use of shared algorithms for out-of-network repricing.
Failure to meet the updated FY 2026 revenue guidance floor of $985 million.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.